This study provides a compound backbone for the development of novel SHP2 inhibitors and an experimental basis for preclinical studies based on SHP2 and XIAP dual‐target inhibition, which serve as clinically actionable targets for the treatment of KRAS‐mutant NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.